57 results about "Symptomatic treatment" patented technology

The invention discloses an engineered exosome for promoting hair regeneration and a preparation method and application thereof, Wnt10b gene is inserted into a plasmid vector to construct a target plasmid, the target plasmid and a lentivirus packaging plasmid are co-transfected to packaging cells to generate lentivirus particles, and then target stem cells are infected. Screening to obtain a cell strain capable of stably expressing a target gene, culturing the stably transfected strain, and collecting the engineered exosome generated by the stably transfected strain. The exosomes are rich in Wnt10b protein and can promote proliferation and differentiation of hair follicle stem cells on a molecular level, so that hair follicle tissues in a resting period are activated and enter a growing period again, and hair regeneration is realized. Meanwhile, the exosome is high in safety, and adverse reactions caused by traditional chemical synthesis drugs are avoided. The exosome can be applied to the preparation of hair regeneration products, and the accurate symptomatic treatment capability of the exosome provides a hair growth method aiming at pathogenesis for alopecia patients, and provides a new hope for patients who seek safe and effective hair growth solutions.

The present invention relates to the field of biochemical and pharmaceutical technologies, and in particular to a continuous enzymolysis enrichment modification and purification utilization method for xanthohumol flavonoid. The method comprises the following steps: S1, continuous enzymolysis; S2, recovery of complex enzymes; S3, heterologous expression; S4, electrodialysis-reverse osmosis purification; and S5, structural modification. Compared with the prior art, on the basis of lignite humic acid and fulvic acid gap enzymolysis, the use of continuous enzymolysis enrichment modification and purification utilization to obtain a dietetic and medical product xanthohumol flavonoid having a clear composition structure and capable of symptomatic treatment has remarkable progress and substantive effects in the aspects of product quality, low-carbon emission and environmental friendliness compared with chemical extraction.

The invention discloses application of Ipriflavone in resisting respiratory syncytial virus infection, and belongs to the technical field of biological medicine. Specifically, a small molecule compound library is screened to obtain a compound Ipriflavone with a relatively good inhibition effect on the RSV virus, the effective and safe dosage of the compound Ipriflavone is explored, the obtained medicine can remarkably inhibit replication of the RSV virus, and the feasibility of the medicine in resisting RSV virus infection is proved through in-vivo experiments. The invention provides a new strategy for preventing and treating respiratory syncytial virus infection, which is expected to overcome the defects of traditional symptomatic treatment and treatment support, and provides a new choice for clinical prevention and treatment of RSV virus.

As a common complication, hydrothorax and ascites are poor in prognosis in a clinical intervention mode mainly based on symptomatic treatment. Under the guidance of a new theory of'inflammation-cancer 'transformation, the invention discloses a traditional Chinese medicine composition for preventing and treating hydrothorax and ascites and a preparation method for oral administration and external application. The composition comprises the following traditional Chinese medicinal materials in parts by mass: 3-20 parts of codonopsis pilosula, 3-20 parts of raw bighead atractylodes rhizome, 3-18 parts of cassia twig, 3-18 parts of radices trichosanthis, 3-12 parts of pseudo-ginseng, 3-15 parts of Chinese lobelia, 3-15 parts of bistort rhizome, 3-15 parts of euphorbia helioscopia and 3-15 parts of semen lepidii. The traditional Chinese medicine composition disclosed by the invention has the effects of strengthening the body resistance, dispersing blood stasis, detoxifying, clearing damp, inducing diuresis and diminishing swelling, and has good effects on preventing and treating inflammatory hydrothorax and ascites and malignant hydrothorax and ascites as well as dyspnea, chest pain, cough, anorexia, abdominal pain, abdominal distension, weakness, night sweat and the like caused by the inflammatory hydrothorax and ascites and the malignant hydrothorax and ascites. The preparation method comprises decoction, granules, pills, capsules and powder. The traditional Chinese medicine composition is helpful for promoting absorption and discharge of hydrothorax and ascites, diminishing inflammation and resisting cancer, adjusting and recovering physiological functions of internal organs, and improving life quality of patients.

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

To provide a system.SOLUTION: A system includes: means for inputting a symptom of a disease by a user; means for providing a necessary coping therapy or a medicine on the basis of the inputted symptom; and means capable of performing primary coping in real time.SELECTED DRAWING: Figure 1

The invention discloses a stagnation-removing composition as well as a preparation method and application thereof, on the basis of four-adverse-qi powder consisting of radix bupleuri, immature bitter orange, red peony root and honey-fried licorice root, liver and spleen qi is regulated and smoothened, and the ascending and descending functions of intestinal tracts are recovered; the fructus kochiae, the fructus cnidii, the fried peach kernels, the fried semen armeniacae amarae, the Chinese waxgourd seeds fried with bran, the ligusticum wallichii, the lumbricus and the schizonepeta spike are creatively combined, so that the effects of promoting blood circulation to remove blood stasis, promoting diuresis to dispel wind and relaxing bowel are synergistically achieved. According to the traditional Chinese medicine composition, the difficulty in defecation can be effectively improved, the pathological links of qi stagnation, damp obstruction and blood stasis can be intervened from the pathogenesis, various uncomfortable symptoms related to abdominal fullness, anus falling expansion, vector qi frequency and the like can be remarkably relieved, the conversion from treatment according to noses to treatment for the root is realized, and a solution with more comprehensive effects and more lasting curative effects is provided.

The present invention discloses the use of CircSS18 in a drug for the treatment of osteoarthritis and a method for its preparation. Local intra-articular injection of a nano-controlled-release hydrogel composite overexpressing circSS18 has significant potential clinical value in the targeted treatment of osteoarthritis: 1. Compared with current clinical local intra-articular injections of sodium hyaluronate and platelet-rich plasma (PRP), this method has a clear target and mechanism of action, making the treatment more targeted and effective, and a curative approach. 2. Compared with current clinical oral symptomatic treatments such as NSAIDs and glucosamine, this method can fundamentally inhibit the progression of osteoarthritis. 3. Compared with surgical procedures such as arthroscopy and joint replacement, this method is less invasive, less expensive, more feasible, and more practical, making it more acceptable to patients.

The invention relates to the technical field of emergency detection, in particular to a method for detecting dephosphorylated nummulina velutipes and toad tryptamine in a urine sample. According to the method, a to-be-detected urine sample is detected by adopting an Online SPE-LC-MS / MS method, a liquid chromatographic column is a BEH-filled C18 chromatographic column, and a solid phase extraction column is an online HLB (Hydrophile Lipophile Balance) small column. According to the method, online purification and enrichment of the sample can be automatically completed, the analysis time is short, the requirement for the dosage of the urine sample is small, complex sample pretreatment is not needed, the detection limit can reach 0.03 ng / mL, and the method has good sensitivity and accuracy and can meet the analysis requirement of the actual sample. The method is of great significance to identification of food poisoning sources and symptomatic treatment of patients.

The invention relates to a nano prodrug as well as a preparation method and application thereof, and belongs to the technical field of nano preparations. Two nano prodrugs based on a hyperbranched polymer and an amphiphilic random copolymer are constructed, the hyperbranched polymer takes a mercaptosuccinic acid small molecule as a metal ion chelating agent, and a novel hyperbranched polymer which is rich in a thioacetal branched structure inside and is modified by mannose on the surface is constructed through sulfydryl-alkyne click chemistry and esterification. The amphiphilic random copolymer is prepared by carrying out reversible addition-fragmentation chain transfer polymerization on a functional chelating monomer (DSF) with ROS responsiveness and PEG (Polyethylene Glycol) with targeted group-mannose. The two nano prodrugs have the characteristics of inert circulation, macrophage precise targeting, pathological microenvironment dynamic response exposed copper chelation sites and the like, intracellular overloaded copper ions can be efficiently removed, the limitation of traditional symptomatic treatment is broken through, and a brand new strategy is provided for acute liver injury prevention and treatment.

This application relates to the field of medical diagnosis and treatment technology, specifically to a modular AI-powered fully intelligent diagnostic and treatment instrument and robot for both traditional Chinese medicine (TCM) and Western medicine. It includes: a TCM data acquisition module that constructs a four-diagnostic system (inspection, auscultation, inquiry, and palpation) to acquire TCM data; a Western medicine data acquisition module that constructs a four-diagnostic system (inspection, auscultation, inquiry, and palpation) to acquire Western medicine data; an AI-integrated TCM-Western medicine diagnostic module that uses an improved algorithm based on the fusion theorem definition formula method, Hua Luogeng optimization method, and quantum resonance correction to quantify the TCM data through weighted calculations and pulse diagnosis based on the principles of deficiency and excess; and a module that uses core calculation formulas to analyze the Western medicine data and outputs a TCM-Western medicine integrated diagnostic conclusion; and a treatment plan output module that generates an integrated TCM-Western medicine treatment plan based on the diagnostic conclusion. This integrated TCM-Western medicine treatment plan includes a precise TCM formula combining the principal, assistant, and adjuvant herbs, as well as a Western medicine symptomatic treatment plan. This addresses issues such as the ambiguity of the four diagnostic methods, invasive testing, and insufficient synergy between TCM and Western medicine.

The invention provides a drug rehabilitation traditional Chinese medicine composition. The drug rehabilitation traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 9.6 to 14.4 parts of American ginseng, 17.6 to 26.4 parts of astragalus membranaceus, 10.4 to 15.6 parts of bighead atractylodes rhizome, 10.4 to 15.6 parts of poria cocos, 8 to 12.5 parts of liquorice, 9.6 to 14.4 parts of angelica sinensis, 8 to 12.5 parts of rhizoma picrorhizae, 12 to 18 parts of honeysuckle, 8.8 to 13.2 parts of husks of millet, 8 to 12 parts of catechu, 10.4 to 15.6 parts of durac, 10.4 to 15.6 parts of radix rehmanniae, 10.4 to 15.6 parts of gentiana macrophylla, 10.4 to 15.6 parts of fructus alpiniae oxyphyllae and 17.6 to 26.4 parts of corydalis tuber. The invention further provides a preparation method, application and a quality detection method of the traditional Chinese medicine composition. Experiments prove that the traditional Chinese medicine composition is small in toxic and side effects, stable and controllable in curative effect and low in resorption rate, the acting point is that a large number of tonifying medicines are used for rescuing people firstly, and the symptom is treated by using the symptom-treating medicines, so that the body is recovered as soon as possible, and the treatment compliance of a user who eliminates the abstinence symptom is improved.

The invention provides a genetically engineered drug for treating brain injury and a preparation method thereof. The preparation method specifically comprises the following operation steps: S1, sampling, extracting and mixing biological enzyme; s2, transferring genes, and culturing mother cells; and S3, preliminary separation and in-vivo experiment. Brain injury often causes various pathological changes such as encephaledema, nerve cell death and neuroinflammation, and the pathological changes are always carried out simultaneously. Therefore, the complex pathological processes are only symptomatic treatment at present, and after main death related proteins, especially caspase-8 and representative inflammatory factors after injury are detected, the genetic engineering medicine is found to be capable of blocking nerve cell death after brain injury and effectively inhibiting inflammatory response, so that the nerve cell death after brain injury can be inhibited. And therefore, neuronal degenerative change caused by brain injury and formation of encephaledema can be effectively inhibited.

Disclosed are formulations in the form of mucoadhesive tablets useful for treating symptoms caused by xerostomia (dry mouth). The tablets according to the invention comprise hyaluronic acid, choline alfoscerate and ascorbyl palmitate, and are characterised by two concave surfaces that adapt to the oral and gingival mucosa so as to adhere to the oral vestibules or the palate.

This invention relates to the field of biomedical technology and provides the application of taquimod in the preparation of drugs for regulating lymphatic inflammatory responses. Through bioinformatics analysis and cell experiments, this invention demonstrates that taquimod can specifically inhibit the abnormally activated S100A9 / RAGE signaling pathway in lymphatic inflammation, significantly reduce the expression of inflammatory factors, and effectively restore the proliferation, migration, and tube formation function of lymphatic endothelial cells. This provides a novel drug treatment approach based on molecular mechanisms for treating diseases related to lymphatic inflammatory responses such as lymphedema. Furthermore, taquimod, as an oral formulation with proven safety in clinical trials, exhibits good patient compliance and is suitable for long-term use. Compared to existing symptomatic treatments, it holds promise for fundamentally interrupting the vicious cycle of inflammation that drives disease progression, and thus has significant clinical application potential.

The invention relates to an external traditional Chinese medicine for dialectically treating bone diseases, which comprises a permeating medicine, a permeating medicine and a expelling medicine, the permeating medicine comprises the following raw material medicines: garter snake, long-noded pit viper, ground beetle, earthworm, leech, stiff silkworm, centipede, scorpion, pangolin, nidus vespae, arisaema consanguineum schott and pinellia ternate; the transdermal drug comprises a formula 1, a formula 2, a formula 3, a formula 4 and a formula 5; the drug comprises the following raw materials: cantharides, xanthium sibiricum leaves, euphorbia kansui, radix clematidis, semen brassicae, eclipta alba and liquorice. The external traditional Chinese medicine is used for treating bone diseases in a stage-by-stage dialectical manner, and is high in detoxification speed, more thorough in detoxification, short in treatment period and better in treatment effect. The external traditional Chinese medicine is used by adopting a three-step therapy of permeation, permeation and expelling, and by adopting a method of external treatment of internal diseases, comprehensive conditioning, staged medication and symptomatic treatment, the external traditional Chinese medicine is small in patient pain, short in treatment course, quick in effect taking, good in healing effect, free of side injury and side effects, worthy of wide application and popularization and beneficial to vast bone fracture patients.

Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL).

The invention relates to the technical field of traditional Chinese medicine plant extract compositions, in particular to a herbal tea composition for preventing and treating gout and a preparation method and application thereof.The herbal tea composition is prepared from, by weight, 8-12 parts of folium cortex eucommiae, 40-50 parts of amaranthus spinosus, 8-15 parts of pawpaw and 10-15 parts of raw coix seeds. The folium cortex eucommiae, the amaranthus spinosus, the pawpaw and the raw semen coicis in the composition disclosed by the invention have a synergistic effect on clearing away heat and toxic materials, inducing diuresis, expelling turbidity, clearing damp, activating collaterals, protecting kidney and tonifying spleen, and jointly act on uric acid generation and excretion links, so that the overall effect of reducing the serum uric acid level of the composition is remarkably improved; and the composition can effectively relieve red, swollen, hot, painful and other symptoms of gouty joints. The composition mainly benefits from the anti-inflammatory activity of amaranthus spinosus, the tendon relaxing and collateral activating effects of pawpaw, the dampness excreting and joint benefiting effects of raw coix seeds and the overall anti-inflammatory and detumescence effects of the composition, and important symptomatic treatment support is provided for gout patients.

The invention discloses a method and a system for judging cell properties based on cell morphological characteristics. The method comprises the following steps: step S1, manufacturing pleural effusion cast-off cell slides according to preparation operation specifications of pleural effusion sample slides; s2, observing the form of the pleural effusion exfoliated cell slide sample by using an optical microscope, and recording whether each sample form has the following five morphological characteristics: cloud cytoplasm and large secretory vesicles, red villus at the edge of cancer cells, red villus diffusion distribution, villus side length proportion of 1 / 3-1 / 5, and cell nucleus positioned on the opposite side of the villus; and S3, summarizing inspection results, and giving a final report. According to the invention, the method for determining the property of the lung adenocarcinoma sample through a cell morphology technology is of great clinical significance, and can guide clinical symptomatic treatment and prolong the lifetime of a patient.

The present invention provides a composition for preventing or treating neurodegenerative diseases, containing a novel pyridoindole derivative compound as an active ingredient. The present invention departs from a conventional symptomatic treatment that focused on controlling peripheral symptoms of neurodegenerative diseases, particularly various tauopathies caused by Tau protein aggregation, so as to significantly inhibit the interaction between Tau protein and synaptogyrin-3, and thus can achieve the fundamental removal of the cause of neurodegeneration.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating pulmonary arterial hypertension, and effectively solves the problems that the western medicine for treating pulmonary arterial hypertension is limited in curative effect of symptomatic treatment and has many side effects, targeted treatment cannot fundamentally prevent the progress of a disease course and is poor in prognosis, and invasive treatment is relatively large in damage to a body, general in prognosis and high in price. According to the technical scheme, concentrated watered pills are prepared from the following raw medicinal materials by weight: 108 to 132g of astragalus membranaceus, 10 to 20g of bighead atractylodes rhizome, 27 to 33g of rhodiola rosea, 10 to 20g of trichosanthes kirilowii maxim, 27 to 33g of allium macrostemon, 10 to 20g of rhizoma pinellinae praeparata, 27 to 33g of salvia miltiorrhiza, 9 to 11g of safflower, 2.7 to 3.3 g of pseudo-ginseng, 27 to 33g of semen lepidii, 27 to 33g of white mulberry root-bark, 27 to 33g of parasitic loranthus, 45 to 55g of crude dragon bone, 45 to 55g of raw oyster shell, 54 to 66g of kudzu vine root, 45 to 55g of poria cocos, 45 to 55g of coix seed, 27 to 33g of earthworm and 9 to 11g of According to the treatment principle of tonifying qi, reducing phlegm, removing blood stasis and inducing diuresis, the traditional Chinese medicine composition can stably, durably and effectively control pulmonary arterial hypertension, improve the right heart function and control disease progression, and the life quality of patients is fundamentally improved.

The application provides a wearable light therapy device. The device comprises a base band, a plurality of light emitting elements arranged on the base band, and a controller. The controller is configured to determine a target treatment mode for the patient, determine a plurality of adjustment parameters of a first light emitting element group according to the target treatment mode, and control the plurality of light emitting elements to treat the target part of the patient. The target treatment mode is one of a plurality of treatment modes of the light therapy device for treating a target disease. The first light emitting element group is any one of a plurality of light emitting element groups formed by the plurality of light emitting elements, and the plurality of light emitting element groups correspond to a plurality of sub-parts of the target part. The application can select an appropriate target treatment mode according to the patient's symptoms, and achieve symptomatic treatment and improve treatment effect.

The invention relates to the technical field of emergency detection, in particular to a method for detecting dephosphorylated nummulina velutipes and toad tryptamine in a urine sample. According to the method, a to-be-detected urine sample is detected by adopting an Online SPE-LC-MS / MS method, a liquid chromatographic column is a BEHC18 chromatographic column, and a solid-phase extraction column is an online HLB small column. According to the method, online purification and enrichment of the sample can be automatically completed, the analysis time is short, the requirement for the dosage of the urine sample is small, complex sample pretreatment is not needed, the detection limit can reach 0.03 ng / mL, and the method has good sensitivity and accuracy and can meet the analysis requirement of the actual sample. The method is of great significance to identification of food poisoning sources and symptomatic treatment of patients.

The invention discloses a single-molecule joint detection method for Alzheimer's disease markers A beta 1-42, A beta 1-40 and P-Tau181, which comprises the following steps: 1, activating microspheres, and coupling the activated microspheres with antibodies to prepare fluorescent microsphere labeled antibodies, the fluorescent microsphere labeled antibodies comprise microspheres labeled with A beta 1-42 detection antibodies, microspheres labeled with A beta 1-40 detection antibodies, and microspheres labeled with P-Tau181 detection antibodies; 2, preparing a coated antibody immobilization plate, wherein the coated antibody immobilization plate is coated with an A beta 1-42 capture antibody, an A beta 1-40 capture antibody and a P-Tau181 capture antibody; and 3, adding a sample containing A [beta] 1-42, A [beta] 1-40 and P-Tau, a quality control product or a calibration product into the plate coated with the antibody for immobilization, adding the fluorescent microsphere labeled antibody into the plate, detecting by using a digital fluorescence immunoassay instrument, and quantifying the content of A [beta] 1-42, A [beta] 1-40 and P-Tau by analyzing the number of fluorescent particles and matching with a standard curve. According to the kit, the digital fluorescence immunoadsorption technology is adopted, and the three markers A [beta] 1-42, A [beta] 1-40 and P-Tau181 are combined for detection, so that the kit has important clinical values on early diagnosis of AD, risk stratification of diseases and timely symptomatic treatment and prognosis judgment of patients.

The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

The present invention relates to an aqueous liquid composition or a hydroalcoholic liquid which consists of a mixture which consists of or, alternatively, is composed of a combination of Aloe vera gel, hyaluronic acid and honey and optionally, food and / or pharmaceutical grade additives and / or technological excipients. Said composition is intended for use in the preventive and / or therapeutic treatment of symptoms and disorders associated with gastroesophageal reflux and / or laryngopharyngeal reflux (RLF) and the disease caused by it, for use as an adjuvant in the symptomatic treatment of gastroesophageal and / or laryngopharyngeal reflux, or for use in a preventive and / or therapeutic treatment against: (i) lesions of the oral cavity and the pharyngo-laryngopharyngeal tract (ii) mucositis and / or iii) aphthous ulcers and / or aphthous lesions.

The utility model relates to the technical field of moxibustion devices, in particular to a bamboo cup moxibustion device which comprises a bamboo cup, a mounting seat is in threaded connection with the interior of the bamboo cup, an adjusting disc is rotatably connected with the interior of the mounting seat, a fixing needle is slidably connected with the interior of the mounting seat, and a fixing rod is arranged in the fixing needle. And a first protective net is fixedly mounted in the bamboo tank. Compared with the prior art, the moxibustion device has the advantages that medicine dipping cotton dipped with traditional Chinese medicine can be placed in the placing groove formed in the first protective net, the traditional Chinese medicine for symptomatic treatment can act on acupuncture points at the same time, the distance between the moxa cone and the skin of a user can be adjusted through cooperation of the screw rod, the positioning sleeve and the positioning block, and the moxibustion effect is improved. The ventilation effect is controlled through cooperation of the first ventilation grooves and the second ventilation grooves, the combustion speed of the moxa cones can be conveniently controlled, the moxibustion effect can be guaranteed, consumption of the moxa cones can be reduced, the use cost is reduced, and the practicability of the device is further improved.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method and device for predicting a BK virus infection disease stage based on gene expression. The method comprises the following steps: obtaining a tissue sample of a to-be-tested person; obtaining an expression amount of a target gene of a region of interest based on the tissue sample, the region of interest being PanCK+, and the target gene comprising one or more of the following: HLA-DPA1 and LYZ; inputting the expression amount of the target gene of the region of interest into a classifier, and predicting a BK virus infection stage of the to-be-tested person according to an output of the classifier, wherein the BK virus infection stage comprises the following: non-infection, BK viremia, and BK nephropathy. The application realizes the differentiation of BK virus infection stages based on gene expression, and helps to realize symptomatic treatment from the gene expression level.

The application belongs to the field of biological medicine, and provides application of d-borneol in preparation of a drug for preventing and / or treating preeclampsia. A preeclampsia animal model is induced and established by subcutaneous injection of a solution of nitroso-L-arginine methyl ester (125 mg / kg), and d-borneol (15 mg / kg) is given to the animal by gavage from the 9th day of pregnancy every day until the end of pregnancy. Compared with the single treatment effect of the existing clinical commonly used antihypertensive drug labetalol, antispasmodic and anticonvulsant drug magnesium sulfate and the like, the d-borneol of the application not only can relieve hypertension and proteinuria of the preeclampsia model mouse, but also can improve pathological changes such as reduced placental weight, abnormal placental structure and function, intrauterine growth restriction of the fetus, and imbalance of pro-angiogenic factors and anti-angiogenic factors. Meanwhile, the d-borneol can also alleviate the preeclampsia related maternal kidney injury, and shows a more comprehensive intervention effect than the existing symptomatic treatment drug, thereby providing a new treatment drug for preventing or treating preeclampsia.

The present invention provides a composition comprising a novel pyridoindole derivative compound as an active ingredient for preventing or treating neurodegenerative diseases. According to the application disclosed by the invention, the traditional symptomatic treatment which focuses on controlling peripheral symptoms of the neurodegenerative diseases, especially various Tau proteopathies caused by Tau protein aggregation, is abandoned, and the cause of the neurodegenerative diseases is fundamentally eliminated by remarkably inhibiting the interaction between the Tau protein and the synaptic return protein 3.